

Membrane Fatty Acids in Normal and Experimentally Induced Diabetes Mellitus in Rats

Hassanein, M. R.; Hussein, S.A. and El-Haggag, M
Biochem. Dept., Fac. Vet. Med., Moshtohor, Benha Univ.

Abstract

Membrane fatty acids in normal and experimentally induced diabetes mellitus in rats were investigated. This study was carried out on 120 male rats. The rats were divided into two equal groups of 60 rats each. Group I: (control group): Injected with citrate buffer only. Group II: (Diabetic group): Injected with a single intraperitoneal (i.p) injection of 50 mg/kg of streptozotocin for diabetes induction. Blood samples were collected in tubes containing trisodium citrate 3.8 % from all animal groups five times at 2, 4, 6, 8 and 10 weeks from the onset of diabetes induction. Plasma were separated and processed directly for glucose, total cholesterol, triacylglycerols, HDL-C, LDL-C, VLDL-C, NEFA, and L- malondialdehyde (L-MDA) determination. Moreover, total cholesterol, phospholipids and fatty acids composition in erythrocyte membrane were also analyzed. The obtained results revealed that, a significant increase in plasma glucose, total cholesterol, triacylglycerols, LDL-C, VLDL-C, NEFA, L-MDA and significant decrease in HDL-C concentrations were observed in streptozotocin-induced diabetic rats when compared with the non-diabetic control group. Also, a marked decrease in total cholesterol and Phospholipids concentrations were observed in erythrocyte membrane in streptozotocin-induced diabetic (STZ-D) rats. Moreover, fatty acid composition in erythrocytes of STZ-D rats revealed significant decrease in the percent of pentadecyclic and palmitic acids and increase in stearic and arachidic acids percent during different periods of diabetes. From the obtained results it could be concluded that, experimental diabetes mellitus extensively alters and induced disturbances in lipid metabolism in male rats. Also, Streptozotocin induced diabetes in rats alters erythrocyte membrane fatty acid composition.

Introduction

Diabetes mellitus is found in almost all populations and is emerging as a growing problem in developing countries (27). Diabetic patients appear to have an increased incidence of multiple cardiovascular diseases including atherosclerosis, myocardial infarction and congestive heart failure. Furthermore, diabetes often involves a cardiomyopathy which is usually associated with decreased glucose utilization and increased fatty acid oxidation at specific metabolic sites (14).

Fatty acid composition is changed in humans and animals with diabetes. Diabetes inhibits delta-6-desaturase, which converts linoleic acid (LA) into gamma linolenic acid (GLA), the precursor of arachidonic acid and ultimately several vasoactive prostanoids. In experimental and clinical diabetes, GLA production is reduced. Consequently, the levels of dihomo gamma linolenic acid (DGLA), which is a product of GLA elongation, and arachidonic acid. Also are reduced, which results in a decreased production of the prostanoids, prostacyclin, and prostaglandins (43).

Free fatty acids are an improved physiological fuel for islets, and act as a supplemental nutrient secretagogue to potentiate insulin release acutely in the presence of glucose (37). Chronically elevated FFA are believed to play a role in the pathogenesis of certain forms of type H diabetes by both inhibiting insulin stimulated peripheral glucose uptake and contributing to B cell dysfunction (7).

Accordingly, this study was performed to investigate whether streptozotocin-induced diabetes in rats results in alters cholesterol, phospholipids and fatty acids composition of erythrocytes membrane. Moreover, alterations of some plasma lipids composition and lipoprotein profiles as well as lipid peroxidation in diabetic rats were also investigated. The determination of cholesterol, phospholipids and fatty acids composition of erythrocytes membrane in STZ-D rats are useful in establishing the protective role of essential fatty acid nutrient on catabolic consequence of diabetes mellitus induced biochemical abnormalities in male rats.

Materials and Methods

One hundred and twenty white male albino rats, 12- 16 weeks old and average body weight 220- 250 gm were used in this study . Rats were obtained from laboratory animals research center, Faculty of Veterinary Medicine, Moshtohor, Benha University. Rats were housed in separated metal cages and kept at constant environmental and nutritional conditions throughout the period of experiment. Water was supplied ad- libitum.

Experimental design:

*Third Inter. Sci. Conf., 29 Jan.- 1 Feb./ 2009, Benha & Ras Sudr, Egypt
Fac. Vet. Med. (Moshtohor), Benha Univ*

The rats were randomly divided into two main large equal groups, of 60 animals each, placed in individual cages and classified as follows:

Group I: (Control group): Injected with citrate buffer only. **Group II: (Diabetic group):** Injected with streptozotocin after overnight fasting for diabetes induction.

Diabetes Induction:

Rats were fasted for 18 hour and allowed free access of water. The experimental induction of diabetes in male rats was induced by a single intraperitoneal (i.p) injection of 50 mg / kg of streptozotocin (STZ) (sigma Chemical Co. P.O. Box. 14508, St. Louis, U.S.A.) freshly dissolved in citrate buffer, PH 4.5. A week later, STZ-treated rats were fasted for 12 hour, and blood samples were collected from the orbital venous sinus for glucose determination. Only those rats in diabetic group (group II) with blood glucose levels higher than 250 mg/ dl were considered diabetic (33).

Sampling:

Blood samples were collected after overnight fasting by ocular vein puncture from all animal groups, five times, at 2, 4, 6, 8 and 10 weeks from the onset of diabetes induction. Blood samples were collected in screw capped tubes containing an anticoagulant solution, trisodium citrate 3.8 % with PH adjusted to 7.4 with citric acid (1 vol. anticoagulant / 9 vol. blood) and plasma were separated by centrifugation at 2500 r.p.m for 15 minutes. The clean, clear plasma was separated and processed directly for glucose determination, then kept in a deep freeze at - 20 °C until used for subsequent biochemical analysis.

Biochemical analysis:

Plasma glucose, total cholesterol, triacylglycerols, high density lipoprotein cholesterol (HDL-cholesterol), Low density lipoprotein cholesterol (LDL - cholesterol), very low density lipoprotein cholesterol (VLDL- cholesterol), nonesterified fatty acids (NEFA), and L-malondialdehyde (L- MDA) were analyzed colorimetrically according to the methods described by (42), (2), (10), (21), (16), (6), (34), and (15), respectively. Moreover, after plasma separation, erythrocytes were washed for plasma membrane isolation as described by (32) and processed for determination of total cholesterol and phospholipids according to the methods described by (2) and (41), respectively. The methyl ester of fatty acids composition in erythrocyte membrane, were dissolved in pure

*Third Inter. Sci. Conf., 29 Jan.- 1 Feb./ 2009, Benha & Ras Sudr, Egypt
Fac. Vet. Med. (Moshtohor), Benha Univ*

chloroform and an aliquots of this solution were subjected to gas-liquid chromatography (GLC) analysis, according to the method of (46).

Statistical analysis:

Statistical analysis of the results was carried out using student's T-test according to (25).

Results and Discussion

Diabetes represents a common endocrinal disease affecting many metabolic aspects joined mainly with absolute or relative deficiencies in insulin secretion and / or insulin sensitivity (31). Such disease can be characterized by its long-term complications clearly observed in cardiovascular, renal, neural, and visual systems (12). Development of these complications appears to be somewhat related to duration of the disease, specifically prolonged exposure to extreme high glucose level or its metabolites (48).

The obtained results (Table 1) revealed a significant increase in plasma glucose, total cholesterol, triacylglycerols, LDL-C, VLDL-C, NEFA, L-MDA and significant decrease in HDL-C concentrations in streptozotocin-induced diabetic rats when compared with the non-diabetic control group.

The increase in plasma glucose concentration of streptozotocin treated group which came in agreement with (28) who related the developed hyperglycemia to the specific toxic effects have been attributed to STZ uptake through glucose transporter-2 (GLUT-2), these toxic effects lead to end organ damage through activation of the aldose-reductase pathway leading to toxic accumulation of sorbitol in nervous system (20), increased diacylglycerols synthesis with consequent activation of protein kinase C isoform (PKC) in vascular tissue, initiating diabetic complications and Increased oxidative stress with subsequent alterations in cellular redox balance (49).

Regarding, plasma total cholesterol concentration in streptozotocin-induced diabetic (STZ-D) rats the obtained results are nearly similar to the reported studies of (50) who demonstrated that, dyslipidemia is prominent in diabetic and renal failure patients showed TC, TG and LDL-C increase, additionally this atherogenic indexes in agreement with reported studies of (18), who related the atherosclerosis complications and higher in TG level is

predominantly due to reduced lipolysis of triglyceride-rich lipoproteins. In diabetes glycooxidation could be an important pathway for accelerated LDL oxidation through the formation of the reactive oxygen species. So, glycooxidation induced significant damage to lipoproteins (8). In this respect, the characteristic lipid abnormalities in diabetes include higher level of TG, LDL-C, VLDL-C and decreased level of HDL-C. It's the deficiency of insulin may decrease the rates of triacylglycerols removal either from the liver or the circulation (51) which could be also related to the increased activities of HMG-CoA as recorded by (24) who observed that, plasma cholesterol was significantly increased and both hepatic and intestinal 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase activities were significantly higher in Wister fatty rats than those in controls, respectively. On the other hand, ACAT activities in Wister fatty rats were significantly increased in the intestine and decreased in the liver in comparison with controls.

The increase in plasma triacylglycerols concentration were came in accordance with the recorded data of (37) who reported that, hypertriglyceridemia and hypercholesterolemia are frequently observed in diabetics. Increased lipolysis in diabetes may lead to an increased serum level of free fatty acids and glycerol, ketone bodies formation and lastly acidosis. Also, (1) showed that, there was a significant increase in plasma non-esterified cholesterol, triglycerides and phospholipids in STZ-induced diabetic rats, accompanied by a decrease in high density lipoprotein (HDL)-cholesterol. The reported changes in TG could be related to the mild but significant insulin deficiency resulted in mild hypertriglyceridemia, linked to impaired triglyceride removal rather than to an overproduction of VLDL-triglyceride, despite elevated levels of plasma free fatty acids, also it could be attributed to the disturbed tissue lipases system which regulated by insulin were suppressed by STZ increasing TG (19).

In the present study diabetes is associated with lower level of HDL-C and increase level of LDL-C, and VLDL-C. Similarly, (5) showed that, low density lipoprotein (LDL), and very low density lipoprotein (VLDL) demonstrate higher level. The recorded data may be due to deficiency of lipoprotein lipase activity (LPL: insulin dependent enzyme) which plays certain roles in both triacylglycerols removal and HDL-C production, such activity is usually attributed to insulin deficiency (13). Moreover the

*Third Inter. Sci. Conf., 29 Jan.- 1 Feb./ 2009, Benha & Ras Sudr, Egypt
Fac. Vet. Med. (Moshtohor), Benha Univ*

hypertriglyceridemia observed here may be due to either a defect in lipoprotein removal from the plasma or to over production of LDL by the liver defect of removal of these particles may be due to decreased lipoprotein lipase activity an insulin dependent enzyme (44). Triglycerides - rich lipoprotein are occurring simultaneously with decreased HDL-C level that lipoprotein abnormalities are commonly observed in diabetics and expressed as risk factors to atherosclerosis development. (22) recorded that, diabetes resulted in a decrease in HDL-cholesterol. Diabetes resulted in an increase in LDL-apoB but a decrease in LDL-apoE. Who suggested that, hyperlipidemia and low HDL cholesterol levels may be risk factors for the onset of diabetic cataracts and that diabetic cataracts may be accelerated by hyperlipidemia and low HDL cholesterol in rats. Moreover, (45) recorded that, concentrations of very low density lipoproteins (VLDL), low density lipoproteins (LDL), and high density lipoproteins (HDL) of spontaneously diabetic BB and non diabetic littermate rats were higher than those of normal rats.

The recorded decrease in plasma NEFA concentration in diabetic rats was came in accordance with the results of (35) who recorded that, increased lipolysis in diabetes may lead to an increased serum level of free fatty acids and glycerol, ketone bodies formation and lastly acidosis. Increased levels of plasma TGs and NEFA may play certain role in the pathogenesis of insulin-resistant diabetes. In the liver increased NEFA oxidation may stimulate gluconeogenesis, contributing in turn to in appropriate glucose production found in type II diabetic patients. The recorded data could be related to the escaping immediate uptake is a highly regulated process and that impairment of this extraction or entrapment of TG-derived FA may be involved in the pathophysiology of insulin resistance and dyslipidemia as conformed by (17) who reported that, an increase in plasma and liver microsome oleic acid and a decrease in arachidonic acid were found in diabetes and (28) demonstrated that, fasted streptozotocin-induced diabetic animals have increased NEFA levels also (23) observed that, in contrast, the plasma levels of ketone bodies and FFA were significantly increased in STZ-diabetic rats.

The recorded data showed a significant increase in plasma L-MDA in the STZ diabetic rats. Similar results were recorded by (40) who demonstrated that, plasma MDA showed 80 % increase in the early stages of diabetes, and

more progressive increase later which explained as the factors favoring the formation of reactive oxygen species may catalyze lipid peroxidation in the plasma and other tissues and in poorly controlled diabetic, glucose oxidation through the pentose phosphate pathway initiates excessive formation of NADPH, this in turn can promote lipid peroxidation in the presence of cytochrome P- 450 system. The results could be related to the inactivation or inhibition of antioxidant enzymes through glycation, in poorly controlled diabetes mellitus, may give rise high lipid peroxidation rate, evidence of lipid peroxidation had been observed in many diabetic complications.

The obtained results (Table 2) revealed a marked decrease in total cholesterol and phospholipids concentrations of erythrocyte membrane in streptozotocin-induced diabetic rats. Similarly, (26) reported that, the acylation of total phospholipids with palmitic, oleic, or arachidonic acids were decreased in intact erythrocytes from diabetic animals. It also could be attributed to that the erythrocyte membrane composition is altered both in hyperglycemic and hyperlipidemic conditions, and may provide a useful model for evaluating lipid carbohydrate abnormalities of membrane structures in diabetes mellitus (4). Also, the membrane cholesterol/phospholipids ratio is the main reason for decreased membrane fluidity in diabetes, also the composition and structural changes in erythrocyte membranes and compositional changes in plasma lipids may contribute to the development of diabetic complications in diabetes as reported by (9). In this respect (30) showed that, a significant elevation of erythrocyte thiobarbituric acid reactive substances (TBARS), an index of lipid peroxidation and significant reduction in membrane cholesterol and phospholipids content were observed in STZ diabetic rats and the diabetic strain revealed a significant fall in the amount of linoleic acid in liver and kidney microsomes and in erythrocyte membranes.

The obtained results (Table 3) demonstrated that, Fatty acid composition in erythrocytes of (STZ-D) rats revealed significant decrease in the percent of pentadecyclic and palmitic acids and increase in stearic and arachidic acids during different periods of diabetes. Conversely, the total amount of saturated fatty acids was significantly increased and the polyunsaturated/saturated ratio was decreased in the Type 1 diabetic patients. On the other hand, in the erythrocyte membrane, linoleic and stearic acid were higher, and palmitic, palmitoleic, and arachidonic acid

*Third Inter. Sci. Conf., 29 Jan.- 1 Feb./ 2009, Benha & Ras Sudr, Egypt
Fac. Vet. Med. (Moshtohor), Benha Univ*

were lower in diabetic rats. The activities of delta 6 desaturase in diabetic rats were 68% of those of controls, and increased to 119% of controls after insulin treatment. These changes may be related to the changes in radioactive fatty acid incorporation were found in diabetic red cell phosphatidylethanolamine (PE), though they were not statistically significant. The analysis of the membrane phospholipids fatty acid composition revealed a consistent increase of linoleate levels in diabetic rat red cells, a modest decrease of palmitate, oleate, and arachidonate. Lysophosphatidylcholine acyl-CoA transferase (LAT) specific activity measured with either palmitoyl-CoA or oleyl-CoA was significantly reduced in diabetic erythrocyte membranes in comparison to controls and due to the platelet-poor plasma (PPP), the most significant increases in free fatty acids were stearate, linoleate, eicosatrienoate (n-6), and docosahexaenoate (n-3). Also, fatty acid composition of RBC phospholipids was also altered, with significant decreases in arachidonate, docosatetraenoate (n-6), and docosapentaenoate (n-6) and increases in linoleate and docosahexaenoate as shown by (3).

From the obtained results it could be concluded that, experimental induced diabetes mellitus in rats extensively alters and induced disturbances in lipid metabolism. Moreover, composition and structural changes in erythrocyte membranes lipids as well as plasma lipids may contribute to the development of diabetic complications. Because, diabetes induced major changes in plasma and red cell membrane lipid compositions. Therefore, we recommended that, equivalent and adequate amounts of dietary polyunsaturated fatty acids are very essential and should be used with save and therapeutic dose level which may attenuate the adverse and dangerous effects of diabetes or may improve the progression of the disease.

References

1. Ahmed, I. ; Lakhani, M. S. ; Gillett, M. ; John, A. and Raza, H. (2001): Hypotriglyceridemic and hypocholesterolemic effects of anti-diabetic Momordica charantia (karela) fruit extract in streptozotocin-induced diabetic rats Diabetes Res Clin Pract. Mar; 51(3):155-161.
2. Allain, C. C.; Poon, L. S.; Chan, C. S. G.; Richmond, W. and Fu, P. C. (1974): Enzymatic determination of total serum cholesterol. Clin. Chem. 20: 470 – 475.
3. Arduini, A. ; Dottori, S. ; Sciarroni, A. F. ; Corsico, N. ; Morabito, E. ; Arrigoni-Martelli, E. and Calvani, M. (1995) : Effect of propionyl-L-carnitine treatment on membrane phospholipids fatty acid turnover in diabetic rat erythrocytes. Mol Cell Biochem. Nov 8; 152(1):31-37.
4. Arduini, A.; Mancinelli, G. and Ramsay, R. R. (1990): Palmitoyl-L-carnitine, a metabolic intermediate of the fatty acid incorporation pathway in erythrocyte membrane phospholipids. Biochem Biophys Res Commun. Nov 30; 173(1):212-217.
5. Assumpta, C.; Jordi O. L.; Alberto, D. L.; Payes, A. and Perz A. (1997): Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients. Diabetes, 46: 1207-1213.
6. Bauer, J. D. (1982): "Clinical laboratory methods" 9th Ed, the C.V. Company Waistline Industrial Missouri 63116 Chapter 33, p.555.
7. Boden, G. (1997): Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 46: 3-10.
8. Brownlee, M. (1996): Advanced glycation end products in diabetic complications. Curr. Opin. Endocrinol. Diabetes. 3: 291-297.
9. Bryszewska, M. ; Watala, C. and Torzecka, W. (1986) : Changes in fluidity and composition of erythrocyte membranes and in composition of plasma lipids in type I diabetes. Br J Haematol. Jan; 62 (1): 111-116.
10. Bucolo, G. and David, H. (1973): Quantitative determination of serum triglycerides by use of enzymes. Clin. Chem. 19: 476 – 482.
11. Clarke, S. D. (2000): Br. Nutri. 83. (suppl.):59-66. *Clin et al., 1997*
12. Clin, G. W.; Manussan, I.; Laurent, D. and Shulman, G. L. (1997): Mechanism of impaired insulin stimulated muscle glucose metabolism in subject with insulin-dependent diabetes mellitus. J. clin. Invest.; 9: 219-224.
13. De-Fronzo, R. A. and Ferrannini, E. (1991): Insulin Resistance: a multifaceted syndrome responsible for NIDDM, Obesity, Hypertension, dyslipidemia, and atherosclerotic cardio-vascular disease. Diabetes Care. 14: 173- 194.
14. Durbyank, S. W.; Reavely, M.; Seed, M. ; Lane, D. H.; Irland, H.; O'Donnell, O'conner, B.; Noble, M. I.; Davis, R. and Leslie, G. (1994): Risk factors for cardiovascular disease in IDDM. A study of identical twins. Diabetes. 43: 831-835.
15. Esterbauer, H.; Cheeseman, K. H.; Danzani, M. U.; Poli, G. and Slater, T. F. (1982): Separation and characterization of the aldehyde products of ADP/ Fe 2+ C stimulated lipid peroxidation in rat liver microsomes. Biochem.J. 208: 129 -140.

16. Friedewald, W. T.; Levy, R. I. and Fredrickson, D. S. (1972): Estimation of concentration of LDL-cholesterol in plasma, without use of preparative ultracentrifuge. *Clin. Chem.* 18, 499-502.
17. Giron, M. D.; Sanchez, F.; Hortelano, P.; Periago, J. L. and Suarez, M.D. (1999): Effects of dietary fatty acids on lipid metabolism in streptozotocin-induced diabetic rats. *Metabolism.* Apr; 48(4):455-460.
18. Goldfarb-Rumyantzev, A. S. and Passas, L. (2002): prediction of renal insufficiency in pima Indians with nephropathy of type-2 diabetes mellitus. *Am. J. Kidney Dis.*, 40(2):252-264.
19. Gorska, M.; Rutkiewicz, J. and Gorski, J. (1990): The role of insulin in the control of triacylglycerol (TG) in the rat skeletal muscles. *Acta Physiology Pol.*; 41(4-6): 171-176.
20. Greene D. A.; Lamttr, S. A. and Sima, A. F. (1987): Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetes complications. *N. Engl. J. Med.*; 316: 599-606.
21. Grove, T. H. (1979): Effect of reagent pH on determination of high-density lipoprotein cholesterol by precipitation with sodium phosphotungstate – magnesium. *Clin. Chem.* 25: 560 – 564.
22. Hennig, B. and Dupont, J. (1983): Lipoprotein lipid and protein responses to dietary fat and diabetes in rats. *J Nutr.* Oct; 113(10):1984-94.
23. Iguchi, A.; Miura, H.; Kunoh,; Mizuno, S.; Uemura, K.; Ishigura, T.; Tamagawa, T.; Goshioma, K. and Sakamoto, N. (1991): Reciprocal change of plasma glucose and keton bodies in fasted and acutely diabetic rats after CNS Stimulation. *Life. Sci.* 49 (16): 1191-1196.
24. Jiao, S. ; Matsuzawa, Y. ; Matsubara, K. ; Kubo, M. ; Tokunaga, K. ; C daka, H. ; Ikeda, H. ; Matsuo, T. and Tarui, S. (1991) : Abnormalities of plasma lipoproteins in a new genetically obese rat with non-insulin-dependent diabetes mellitus (Wistar fatty rat). *Int J Obes. Jul;* 15(7):487-495.
25. Kempthorn, O. (1969): The design and analysis of experiments; JohnWiley and Sonsine (editor), New York, 47: 96.

26. Le Petit-Tthevenin, J.; Nobili, O. and Boyer, J. (1988): Decreased acylation of phosphatidylcholine in diabetic rat erythrocytes. *Diabetes*. Feb; 37(2):142-146.
27. Mahesh, T. and Menon, V. P. (2004): Quercetin alleviates oxidative stress in streptozotocin-induced diabetic rats. *Phytother Res*. Feb; 18(2): 123-127.
28. Mello, L. E.; Bortolotto, Z. A. and Cavalheiro, E. A. (1988) : Brain indoleamines in alloxan- and streptozotocin-induced diabetic rats. *J. Neurochem*. Sep; 51 (3): 698 - 703.
29. Neilsen K., Karlsen, A. E.; Deckert, M.; Madsen, O. D.; Serup, P.; Mandrup-poulsen, T. and Nerup, J. (1999): B-cell maturation lead to in vitro sensitivity to cytotoxins. *Diabetes*; 48: 2324-2332.
30. Parkasam, A. L.; Sethupathy, S. and Pugalendi, K. V. (2003): Erythrocyte redox status in streptozotocin diabetic rats: effect of *Casearia esculenta* root extract. *Pharmazie*. 58 (12): 920-924.
31. Petres, A. L. and Schringer D. L. (1998): The new diagnostic criteria for diabetes? The impact on management of diabetes and macro vascular risk factor. *Am. J. Med.*; 9: 15-19.
32. Peuchant, E.; wolff, R.; Salles, C. and Jensen, R. (1989): One-step extraction of human erythrocyte lipids allowing rapid determination of fatty acid composition. *Analyt. Bioch.* 181: 341-344.
33. Rammanathan, M.; Jaiswal, A. K. and Bhattacharya, S. K. (1999): Superoxide dismutase, catalase and glutathione peroxidase activities in the brain of streptozotocin induced diabetic rats. *Indian. J. Exp. Biol.*, 37: 182- 183.
34. Schuster, (1979): Estimation of free fatty acids. *Clin. Biochem*. 8:24.
35. Sivan, E.; Homko, C.I.; Whittaker, P. G.; Reece, E. A. and boden, G. (1998): Free fatty acids and insulin resistance during pregnancy. *J. Clin. Endocrinol. Metab.* 83: 2338-2342.
36. Stein, B.; Weintraab, W.S; Gebhart, S.S.P.; Cohen – Bernstein, R. and Liberman, H.A. (1995): Influence of diabetes mellitus on early and late outcome after PTCA. *Circulation*. 91: 979 – 989.
37. Stein, D. T.; Stevenson, B.; Chester, M.; Basit, M.; Daniels, M.; Turley, S. and McGarry, J. (1997): The insulinotropic potency Of fatty acids are influenced profoundly by their chain length and degree of saturation. *J. Clin. Invest.* 100: 398-403.
38. Steinberg, D. Pathasarathy, S.; Carew, T.E.; Khoo J. C. and Witztum, J.L. (1989): Beyond cholesterol: modification of low- density lipoprotein that Increases its atherogenicity. *J. Engl. J. Med.* 32: 915 – 924.
39. Steiner, G. (1991): Altering triglyceride concentrations changes Insulin-glucose relationships in hypertiglyceridemic patients; Double blind study with gemfibrozil with implications for atherosclerosis. *Diabetes care*. 14: 1077 – 1081.
40. Sunduram, K. R.; Bhaskar, A.; Mohan, R. and Shanmugasu-Ndaram, R. K. (1996): *Clinical Science* 90: 255-260.
41. Takeyama, M.; Itoh, S.; Nayasaki, T. and Tanimazu, I. (1977): *Clin. Chem. Acta*. 79: 93.
42. Trinder, P. (1969): *An. Clin. Biochem*. 6: 24.

43. Tsimaratos, M.; Coste, T. C. and Djemli-shipkolye, A. (2001): Gamma- linolenic acid restores renal medullarey thick ascending limb Na^+ , K^+ - Atpase activity in diabetic rats. *J. Nutr.* 131 (12): 3160-3165.
44. Tsustumi, M.; Inou, Y.; Shina, A. and Murase (1993): The noval compound N-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol and long-term administration inhibits atherosclerosis in coronary arteries of rats with experimental atherosclerosis. *Clin. Invest.*, 92: 411-417.
45. Tsutsumi, K.; Inoue, Y. and Yoshida, C. (1999): Acceleration of development of diabetic cataract by hyperlipidemia and low high-density lipoprotein in rats. *Biol Pharm Bull. Jan*; 22 (1): 37-41.
46. Vogel, A. J. (1975): A text book of practical original chemistry. 3rd Ed .P.969-971, English Language Book Society and Longman Group Ltd.London.
47. Walter, A. and Gutknech, J. (1984): Monocarboxylic acid permeation through lipid bilayer membranes. *J. Membr. Biol.* 77: 255-264.
48. Wang, P. H. and Kore, M. (1995): For holly grill: The cause of diabetes (letter). *Lancet*, 346:54.
49. Williamson, J. R.; Chang, K.; Kilo, C. and Tilton, R. G. (1993): Hyperglycemic pseudo hypoxia and diabetic complications. *Diabetes*, 42: 801-813.
50. Yeh, S.L; Tasi, J.C. and Chen, W.J. (1998): Effects of soybean oil and fish oil emulsions on glucose and lipid metabolism in streptozotocin-induced diabetic rats receiving total
51. Yoshino, G.; Matsushita, M. ; Iwai, M. ; Morita, M. ; Matsuba, K. ; Nagata, K. ; Maeda, E. ; Furukawa, S. ; Hirano, T. and Kazumi, T. (1992) : Effect of mild diabetes and dietary fructose on very-low-density lipoprotein triglyceride turnover in rats. *Metabolism. Mar*; 41(3): 236 - 40.

Table (1): Plasma Glucose, Total Cholesterol, Triacylglycerols, HDL-C, LDL-C, VLDL-C (mg/dL), NEFA (mmol/L) and L – MDA (nmol/L) concentrations in streptozotocin-induced diabetic male rats and their control.

Parameters Duration	Glucose		Total Cholesterol		Triacylglycerols		HDL-C		LDL-C		VLDL-C		NEFA		L - MDA	
	Control	Diabetic	Control	Diabetic	Control	Diabetic	Control	Diabetic	Control	Diabetic	Control	Diabetic	Control	Diabetic	Control	Diabetic
2 weeks	83.81	231.97	86.00	95.71 ±	65.33	89.43 ±	13.07	17.89	18.94	17.02	51.28	60.81	3.68	4.56	16.16	16.48
	±	±	±	4.49	±	6.74*	±	±	±	±	±	±	±	±	±	±
	2.87	2.69***	3.96		1.70		0.34	1.35*	1.03	2.00	3.94	5.44	0.15	0.27	0.52	0.23
4 weeks	94.16	329.67	83.33	82.70	57.17	76.57	11.43	15.31	15.84	16.98	54.84	50.42	3.10	3.98	16.00	16.48
	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±
	1.04	2.01***	1.61	4.41	1.50	6.02*	0.30	1.20*	0.78	1.08	2.14	4.54	0.09	0.04	0.77	0.20
6 weeks	95.83	392.86	84.00	99.43	62.14	102.14	12.43	20.43	27.69	20.67	39.74	58.33 ±	3.15	4.77	16.96	17.52 ±
	±	±	±	±	±	±	±	±	±	±	±	2.72**	± 0.28	±	±	±
	2.52	2.53***	3.21	1.51	2.19	7.05**	0.44	1.41**	1.06	2.10*	1.72		0.41*	0.55	0.50	
8 weeks	106.67	236.19	80.83	91.21 ±	69.00	95.00	13.80	19.00	24.10	16.41	42.05	55.80	2.60	3.47	15.44	15.76
	±	±	±	4.07	±	±	±	±	±	±	±	±	±	±	±	±
	2.91	7.25***	2.37		2.71	5.76**	0.54	1.15**	1.50	0.59**	2.25	3.89*	0.27	0.41	0.35	0.37
10 weeks	84.92	261.4	88.00	77.14	66.43	73.57	13.29	16.14	15.33	17.12	56.46	45.30	3.58	3.91	15.92	17.44
	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±	±
	2.37	3.64***	2.80	1.91	2.97	7.03	0.59	1.14	0.98	0.58	1.88	2.49*	0.13	0.46	0.23	0.41*

Data are presented as Mean ± S. E. S. E. = Standard error *: Significant at (P<0.05) **: Highly significant at (P< 0.01) ***: Very highly significant at (P< 0.001)

Table (2): Total cholesterol and phospholipids concentrations of erythrocyte membrane in Streptozotocin-induced diabetic male rats and their control ($\mu\text{mol}/10^{11}$ red cells).

Parameters	Total Cholesterol		Phospholipids	
	Control	Diabetic	Control	Diabetic
Two weeks	20.99 \pm 0.31	17.91 \pm 0.27***	17.37 \pm 0.13	13.94 \pm 0.50**
Four weeks	20.93 \pm 0.79	18.58 \pm 0.46*	19.92 \pm 0.21	14.41 \pm 0.21***
Six weeks	19.18 \pm 0.69	17.28 \pm 0.50	15.79 \pm 0.29	11.89 \pm 0.98*
Eight weeks	20.80 \pm 0.71	17.60 \pm 0.24**	16.36 \pm 0.10	15.01 \pm 0.47*
Ten weeks	19.88 \pm 0.21	18.44 \pm 0.21**	17.42 \pm 0.21	16.88 \pm 0.45

Data are presented as Mean \pm S. E. S. E. = Standard error *: Significant at ($P < 0.05$)
 : Highly significant at ($P < 0.01$) *: Very highly significant at ($P < 0.001$)

Table (3): Fatty acid composition percentage and main fatty acid changes in erythrocyte membrane in streptozotocin- induced diabetic male rats and their control.

Animal groups Fatty acids	Two weeks		Four weeks		Six weeks		Eight weeks		Ten weeks	
	Control	Diabetic	Control	Diabetic	Control	Diabetic	Control	Diabetic	Control	Diabetic
pelargonic C9 : 0	0.24±0.11	0.035±0.005	0.24±0.09	ND	0.18±0.03	0.06±0.01	0.21±0.05	ND	0.32±0.05	0.85±0.40
Capric C10 : 0	ND	ND	4.33±1.02	ND	3.06±0.73	ND	2.52±1.16	ND	1.29±1.05	1.76±0.26
Lauric C12 : 0	7.39±2.57	2.86±0.40	1.17±1.03	3.98±0.57	2.32±0.060	5.19±0.74	2.20±0.78	3.32±0.30	1.85±1.05	8.54±2.76
Myristic C14 : 0	2.46±0.40	0.85±0.38	1.16±0.55	1.50±0.04	1.47±0.21	1.79±0.08	1.90±0.452	1.74±0.18	2.27±1.10	3.67±0.67
Pentadecylic C15: 0	13.72±2.52	25.78±1.75	16.01±5.03	14.26±1.72	23.35±0.60	15.48±0.92*	22.11±1.51	14.12±1.14	25.39±1.72	17.01±3.94
Palmitic C16 : 0	12.27±1.12	4.25±0.48*	7.06±0.60	6.38±0.37	6.67±0.90	7.78±0.28	4.83±1.89	7.54±1.28	6.80±1.30	13.31±1.54
Unknown F. A (1)	12.75±1.30	5.14±0.48*	7.46±0.91	7.70±0.20*	6.24±1.24	9.22±0.36	4.64±1.08	9.52±1.00	7.39±0.88	12.77±2.99
Unknown F. A (2)	8.13±0.69	2.70±0.37*	5.98±1.10	3.76±0.11	4.47±0.77	5.46±0.35	5.06±0.64	6.60±0.53	5.15±0.73	11.10±1.99
Unknown F. A (3)	10.75±0.45	5.78±0.51*	25.24±1.92	7.61±0.20	20.46±1.67	7.59±0.40*	23.88±1.52	7.64±1.08*	28.42±2.97	6.75±2.31*
stearic C18 : 0	12.72±2.40	34.62±1.36*	7.40±3.46	26.15±1.86*	15.98±0.59	25.97±1.38*	16.41±1.02	27.94±2.84	15.21±0.97	12.64±6.39
Oleic C18 : 0	ND	7.98±1.00	14.15±1.45	13.06±0.87	5.16±0.94	9.47±0.38	4.44±2.49	10.51±0.75	3.93±0.82	2.44±0.12
Linoleic C18 : 0	12.18±5.10	0.98±0.63	1.87±0.76	1.91±0.37	1.78±0.77	ND	3.20±0.60	ND	1.64±0.70	8.05±6.25
Linolenic C18 : 0	ND	4.46±0.27	5.58±2.01	7.59±2.97	1.23±0.44	7.11±0.30	ND	6.37±0.42	ND	6.10±1.04
arachidic acid C20:0	2.65±0.15	3.76±1.13	1.01±0.47	4.91±0.35*	ND	4.95±0.11	0.63±0.29	4.19±1.24	ND	ND
Unknown F. A (4)	ND	1.66±0.99	6.16±1.81	1.66±0.36	7.50±0.81	ND	8.76±0.69	ND	3.89±1.80	ND

Data are presented as Mean ± S. E. S. E. = Standard error * : Significant at (P< 0.05) N. D.: Non detectable fatty acids.

F. A= Fatty acids.

الأحماض الدهنية في الفئران الطبيعية والمحدث فيها مرض البول السكري تجريبيا

محمد رجاى رجب حسنين - سامي علي حسين - معدوح كمال الحجار
قسم الكيمياء الحيوية- كلية الطب البيطرى بمشتهر- جامعة بنها

الملخص العربى

يعتبر مرض البول السكرى من أكثر الأمراض انتشارا وشبوعا لتسببه فى كثير من الأمراض مثل تصلب الشرايين وارتفاع ضغط الدم وأيضا لما يحدثه من خلل وزيادة فى دهون الدم ومن هنا جاءت فكرة هذا البحث بهدف معرفة التغيرات الكيميائية الحيوية للأحماض الدهنية المكونة لغشاء كريات الدم الحمراء وكذلك دهون بلازما الدم المصاحبة لمرض البول السكرى المحدث تجريبيا فى فئران التجارب باستخدام مادة الأستربتوزوتوسين. ولقد أجريت الدراسة على عدد ١٢٠ من الفئران البيضاء تتراوح أعمارها بين اثنى عشر إلى ستة عشر أسبوع وأوزانها بين ٢٢٠ - ٢٥٠ جرام قسمت إلى مجموعتين واشتملت كل مجموعة على ٦٠ فأرا وتم توزيع كالاتى : المجموعة الأولى (المجموعة الضابطة) . المجموعة الثانية (المجموعة المحدث بها مرض البول السكرى) تم حقنها بمادة استربتوزوتوسين فى الغشاء البروتونى بنسبة ٥٠ ميللجرام لكل كيلو جرام من وزن الجسم . تم جمع عينات الدم من كل الحيوانات بعد ٢ ، ٤ ، ٦، ٨ ، ١٠ أسابيع فى أنابيب مضاف إليها سترات الصوديوم ، وتم فصل البلازما استخدمت مباشرة لإجراء القياسات البيوكيميائية الآتية : الجلوكوز ، الكوليسترول الكلى ، ثلاثى الجلسريدات والدهون عالية الكثافة والدهون منخفضة الكثافة والدهون منخفضة الكثافة جداً والأحماض الدهنية الحرة إل - مالون داي أدهيد. كما تم قياس الكوليسترول الكلى والفسفوليبيدات والأحماض الدهنية فى غشاء كريات الدم الحمراء . وقد أظهرت النتائج بعد تحليلها إحصائياً على التالى :- وجود زيادة معنوية فى تركيز الجلوكوز ، الكوليسترول الكلى ، ثلاثى الجلسريدات والدهون منخفضة الكثافة والدهون منخفضة الكثافة جداً والأحماض الدهنية الحرة و إل-مالون داي أدهيد مع نقص فى مستوى الدهون عالية الكثافة فى بلازما الدم بالإضافة الى وجود نقص معنوى فى تركيز الكوليسترول الكلى والدهون الفسفورية، وأيضا وجود نقص معنوى فى تركيز كلا من الحامض الدهنى بنتاديسيكك والبهامتيك وزيادة فى تركيز حمض الأراشيدك والأستياريك فى غشاء كريات الدم الحمراء فى الفئران المحدث فيها الداء السكرى عند مقارنتها بالمجموعة الضابطة أثناء بعض فترات التجربة. من ناحية أخرى أسفرت النتائج عن وجود نقص معنوى فى تركيز كلا من الحامض الدهنى بنتاديسيكك والبهامتيك مع وجود زيادة فى تركيز حمض الأراشيدك والأستياريك فى غشاء كريات الدم الحمراء فى الفئران المحدث بها الداء السكرى أثناء بعض فترات التجربة. نظرا لأن مرض الداء السكرى يسبب تغيرات كثيرة فى مكونات دهون الدم وأيضا الدهون المكونة لغشاء كريات الدم الحمراء والذي يؤدى الى حدوث الكثير من المضاعفات والأمراض الأخرى المصاحبة له لذلك نوصى بتناول وجبات مناسبة وأمنة من الأحماض الدهنية الغير مشبعة لما لها من دور أساسى فى الوقاية من الآثار الضارة والخطيرة الناجمة من حدوث هذا المرض.